DEF: ProtoKinetix Seeks Share Increase for Capital Raise

ProtoKinetix, Incorporated is soliciting stockholder consent to increase its authorized common stock from 500 million to 600 million shares to facilitate future capital raises for working capital and general corporate purposes.

Summary

• ProtoKinetix, Incorporated is seeking stockholder approval to amend its Articles of Incorporation to increase the total number of authorized shares of common stock from 500,000,000 to 600,000,000.
• The Board of Directors unanimously approved this action on August 29, 2025, and recommends that stockholders consent to it.
• The purpose of this increase is to facilitate future capital raises through the sale of common stock, with proceeds intended for working capital and general corporate purposes.
• As of the record date, September 5, 2025, the company had 389,080,152 shares of common stock outstanding.
• An additional 94,790,000 shares underlie outstanding options and 8,600,000 shares underlie outstanding warrants, leaving only 1,529,848 shares available for issuance under the current authorization.
• Stockholders must submit their written consent forms by 5:00 p.m. Eastern Time on October 5, 2025.
• Failure to obtain approval could prevent the company from raising sufficient capital to support ongoing operations, potentially leading to liquidation.

Sentiment

Score: 6

Explanation: The filing addresses a critical need for the company to maintain financial flexibility and avoid potential liquidation by increasing its authorized share count. While necessary, it also highlights the company's proximity to its current share limit and its need for additional funding, implying potential future dilution for existing shareholders.

Positives

• The Board of Directors unanimously approved and recommends the action, indicating strong internal support.
• The consent solicitation process is chosen to expedite approval and reduce costs and management time compared to a special meeting.
• Increasing authorized shares provides the company with additional flexibility to raise funds for working capital and general corporate purposes, which is crucial for meeting capital needs.

Negatives

• The company is nearing its current authorized share limit, with only 1,529,848 shares remaining available for issuance.
• Failure to approve the increase in authorized common stock could lead to the company's inability to raise sufficient capital to support ongoing operations, potentially resulting in liquidation.
• Future issuance of additional shares for capital raises will likely result in dilution for existing shareholders.

Risks

• Risk of not obtaining stockholder approval for the proposed increase in authorized common stock.
• If the action is not approved, the company may not be able to raise enough money to support its ongoing operations.
• Potential need to liquidate the company if sufficient capital cannot be raised due to the authorized share limit.
• Dilution of existing shareholders' ownership percentage and voting power upon the issuance of new shares for capital raising.

Future Outlook

The company anticipates using proceeds from future share sales for working capital and general corporate purposes. Failure to approve the increase in authorized shares could prevent the company from raising necessary capital, potentially leading to liquidation.

Management Comments

• "Our Board of Directors believes that approval of this proposal is in the best interests of our Company and our stockholders."
• "The Company has decided to seek the written consent of stockholders through a consent solicitation process rather than holding a special meeting of stockholders in order to expedite the approval process and to eliminate the costs and management time involved in holding a special meeting."
• "Approval of the Action will facilitate the raise of capital through the sale of shares of common stock, resulting in proceeds to the Company, which the Company may use for working capital and general corporate purposes."
• "If we do not obtain authorization to increase our number of authorized common stock, we will not be able to raise enough money to support our ongoing operations and may need to liquidate the Company."

Industry Context

Increasing authorized shares is a common corporate action for growth-oriented companies, particularly those in early or development stages, to ensure flexibility for future capital raises, strategic partnerships, or employee incentive programs. This move aligns with a typical strategy to maintain financial agility and support ongoing operations or expansion without immediate debt financing.

Corporate Governance

Related Party Transactions

• The filing states that, except as disclosed elsewhere, no officer or director or any associate of such person has any substantial interest in the matters acted upon by the Board and stockholders, other than their role as a stockholder, officer, or director.

Stakeholder Impact

• Shareholders: Potential for dilution of ownership and voting power if new shares are issued. The action is crucial for the company's ability to raise capital, which could support growth and prevent liquidation.
• Management: Gains critical flexibility to raise capital for corporate needs, ensuring ongoing operations and strategic initiatives.
• Creditors: Improved financial stability if capital is successfully raised, potentially reducing credit risk associated with the company.

Next Steps

• Stockholders are requested to submit their properly completed and executed Action by Written Consent forms by October 5, 2025.
• The company will publish the final results of the Consent Solicitation in a Current Report on Form 8-K and post them on its website.
• If approved, the company will file a Certificate of Amendment to its Articles of Incorporation with the Secretary of State to effect the increase in authorized shares.
• The company intends to raise capital through the sale of common stock for working capital and general corporate purposes following approval.

Key Dates

Recommendation

The filing indicates a critical need for ProtoKinetix to increase its authorized share count to facilitate future capital raises, which is essential for supporting ongoing operations and avoiding potential liquidation. While the approval of this measure is a positive step towards financial stability and flexibility, it also signals that the company is nearing its current share limit and requires additional funding. The potential for significant shareholder dilution from future share issuances, combined with the underlying need for capital, suggests a 'hold' recommendation. Investors should monitor the outcome of the consent solicitation and subsequent capital raising activities, as well as the terms of any future share issuances, before making further investment decisions.

Keywords

ProtoKinetix, PKTX, SEC filing, DEF 14A, proxy statement, consent solicitation, authorized shares, common stock, capital raise, stock options, warrants, corporate governance, shareholder vote, dilution, working capital